Anti-idiotype colorectal cancer vaccine - GlaxoSmithLine

Drug Profile

Anti-idiotype colorectal cancer vaccine - GlaxoSmithLine

Alternative Names: anti-idiotype goat antibody vaccine SCV 106; SCV 106; SDZ SCV 106

Latest Information Update: 16 Mar 2015

Price : $50

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Epithelial cell adhesion molecule inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 02 Mar 2015 GlaxoSmithKline acquires Anti-idiotype colorectal cancer vaccine from Novartis
  • 02 Feb 2000 A clinical study has been added to the adverse events section and the Cancer therapeutic trials section
  • 02 Feb 2000 Investigation in Cancer in Switzerland (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top